|
Runben Biotechnology (603193.SS) DCF -Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Runben Biotechnology (603193.SS) Bundle
Gewinnen Sie einen Einblick in Ihre Runben Biotechnology (603193SS) Bewertungsanalyse mit unserem ausgefeilten DCF -Taschenrechner! Diese Excel -Vorlage wird mit authentischen (603193S) Daten vorinstalliert, sodass Sie Prognosen und Annahmen anpassen können, um den intrinsischen Wert der Runben -Biotechnologie genau zu bestimmen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442.8 | 582.1 | 856.1 | 1,033.0 | 1,318.2 | 1,736.0 | 2,286.3 | 3,011.0 | 3,965.4 | 5,222.3 |
| Revenue Growth, % | 0 | 31.46 | 47.06 | 20.66 | 27.61 | 31.7 | 31.7 | 31.7 | 31.7 | 31.7 |
| EBITDA | 118.8 | 152.7 | 209.3 | 290.1 | 373.3 | 464.9 | 612.3 | 806.4 | 1,062.0 | 1,398.6 |
| EBITDA, % | 26.83 | 26.23 | 24.45 | 28.08 | 28.32 | 26.78 | 26.78 | 26.78 | 26.78 | 26.78 |
| Depreciation | 8.0 | 10.5 | 19.8 | 21.9 | 21.1 | 33.5 | 44.1 | 58.1 | 76.5 | 100.7 |
| Depreciation, % | 1.81 | 1.81 | 2.31 | 2.12 | 1.6 | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
| EBIT | 110.8 | 142.2 | 189.5 | 268.2 | 352.1 | 431.4 | 568.2 | 748.3 | 985.5 | 1,297.9 |
| EBIT, % | 25.03 | 24.42 | 22.14 | 25.96 | 26.71 | 24.85 | 24.85 | 24.85 | 24.85 | 24.85 |
| Total Cash | 81.7 | 262.4 | 376.5 | 262.8 | 1,355.7 | 808.8 | 1,065.2 | 1,402.8 | 1,847.4 | 2,433.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.2 | .0 | 7.1 | 8.8 | 18.2 | 13.9 | 18.3 | 24.2 | 31.8 | 41.9 |
| Account Receivables, % | 0.94357 | 0 | 0.83321 | 0.85395 | 1.38 | 0.80222 | 0.80222 | 0.80222 | 0.80222 | 0.80222 |
| Inventories | 45.2 | 56.9 | 102.7 | 92.9 | 118.6 | 173.5 | 228.5 | 300.9 | 396.3 | 522.0 |
| Inventories, % | 10.21 | 9.77 | 12 | 8.99 | 9 | 9.99 | 9.99 | 9.99 | 9.99 | 9.99 |
| Accounts Payable | 13.3 | 46.4 | 47.6 | 52.7 | 61.1 | 91.2 | 120.1 | 158.2 | 208.3 | 274.3 |
| Accounts Payable, % | 3 | 7.97 | 5.56 | 5.1 | 4.64 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 |
| Capital Expenditure | -58.2 | -152.0 | -40.7 | -13.7 | -74.2 | -176.9 | -233.0 | -306.9 | -404.2 | -532.3 |
| Capital Expenditure, % | -13.14 | -26.12 | -4.75 | -1.32 | -5.63 | -10.19 | -10.19 | -10.19 | -10.19 | -10.19 |
| Tax Rate, % | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 | 14.73 |
| EBITAT | 95.2 | 121.1 | 161.1 | 226.2 | 300.3 | 367.4 | 483.8 | 637.2 | 839.1 | 1,105.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 8.9 | 5.2 | 88.5 | 247.7 | 220.6 | 203.3 | 264.4 | 348.2 | 458.6 | 603.9 |
| WACC, % | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,398.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 616 | |||||||||
| Terminal Value | 8,889 | |||||||||
| Present Terminal Value | 5,796 | |||||||||
| Enterprise Value | 7,194 | |||||||||
| Net Debt | -105 | |||||||||
| Equity Value | 7,299 | |||||||||
| Diluted Shares Outstanding, MM | 406 | |||||||||
| Equity Value Per Share | 18.00 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-filled financials for RUNBEN BIOTECHNOLOGY (603193SS).
- Accurate Data: Access to historical data and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly assess how your inputs affect the valuation of RUNBEN BIOTECHNOLOGY (603193SS).
- Professional-Grade Tool: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Customizable Forecast Parameters: Adjust essential inputs such as revenue growth rates, profit margins, and research expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and additional financial metrics.
- High-Precision Accuracy: Utilizes RUNBEN BIOTECHNOLOGY's (603193SS) real financial data for credible valuation results.
- Seamless Scenario Analysis: Effortlessly explore various assumptions and compare resulting outcomes.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template featuring RUNBEN BIOTECHNOLOGY’s data.
- Step 2: Review the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see updated results, which include RUNBEN BIOTECHNOLOGY’s intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the generated outputs.
Why Choose This Calculator for RUNBEN BIOTECHNOLOGY (603193SS)?
- User-Friendly Interface: Suitable for both novices and experienced users.
- Customizable Inputs: Effortlessly adjust parameters to tailor your analysis.
- Real-Time Updates: Watch RUNBEN's valuation change instantly as you modify inputs.
- Preloaded Data: Comes with RUNBEN’s actual financial figures for efficient assessment.
- Relied Upon by Experts: A go-to tool for investors and analysts seeking to make well-informed choices.
Who Should Consider RUNBEN BIOTECHNOLOGY (603193SS)?
- Individual Investors: Gain insights to make informed decisions regarding investments in RUNBEN BIOTECHNOLOGY (603193SS).
- Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for RUNBEN BIOTECHNOLOGY (603193SS).
- Consultants: Provide clients with accurate and timely valuation assessments of RUNBEN BIOTECHNOLOGY (603193SS).
- Business Owners: Learn the valuation practices of successful biotechnological firms like RUNBEN BIOTECHNOLOGY (603193SS) to refine your own business strategies.
- Finance Students: Explore real-world valuation techniques using data and examples from RUNBEN BIOTECHNOLOGY (603193SS).
What the Template Includes
- Pre-Filled Data: Contains RUNBEN BIOTECHNOLOGY's historical financials and projections.
- Discounted Cash Flow Model: An editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A specialized sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess RUNBEN BIOTECHNOLOGY's profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing crucial valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.